Roche has swooped to acquire InterMune, the US biotech company behind the potential blockbuster treatment pirfenidone. The Swiss pharma giant will pay $8.3 billion for the company, snatching it ...
Shionogi and InterMune have announced the marketing approval of pirfenidone (Pirespa) for the treatment of idiopathic pulmonary fibrosis (IPF) in Japan, making it the first approved therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback